tetano
Editor, Senior Moderator
Trends Analyt Chem
. 2022 Dec;157:116814.
doi: 10.1016/j.trac.2022.116814. Epub 2022 Nov 7.
Merging microfluidics with luminescence immunoassays for urgent point-of-care diagnostics of COVID-19
Huijuan Yuan[SUP] 1 [/SUP], Peng Chen[SUP] 1 [/SUP], Chao Wan[SUP] 1 [/SUP], Yiwei Li[SUP] 1 [/SUP], Bi-Feng Liu[SUP] 1 [/SUP]
Affiliations
Abstract
The Coronavirus disease 2019 (COVID-19) outbreak has urged the establishment of a global-wide rapid diagnostic system. Current widely-used tests for COVID-19 include nucleic acid assays, immunoassays, and radiological imaging. Immunoassays play an irreplaceable role in rapidly diagnosing COVID-19 and monitoring the patients for the assessment of their severity, risks of the immune storm, and prediction of treatment outcomes. Despite of the enormous needs for immunoassays, the widespread use of traditional immunoassay platforms is still limited by high cost and low automation, which are currently not suitable for point-of-care tests (POCTs). Microfluidic chips with the features of low consumption, high throughput, and integration, provide the potential to enable immunoassays for POCTs, especially in remote areas. Meanwhile, luminescence detection can be merged with immunoassays on microfluidic platforms for their good performance in quantification, sensitivity, and specificity. This review introduces both homogenous and heterogenous luminescence immunoassays with various microfluidic platforms. We also summarize the strengths and weaknesses of the categorized methods, highlighting their recent typical progress. Additionally, different microfluidic platforms are described for comparison. The latest advances in combining luminescence immunoassays with microfluidic platforms for POCTs of COVID-19 are further explained with antigens, antibodies, and related cytokines. Finally, challenges and future perspectives were discussed.
Keywords: COVID-19; Luminescence immunoassays; Microfluidic chips; POCTs.
. 2022 Dec;157:116814.
doi: 10.1016/j.trac.2022.116814. Epub 2022 Nov 7.
Merging microfluidics with luminescence immunoassays for urgent point-of-care diagnostics of COVID-19
Huijuan Yuan[SUP] 1 [/SUP], Peng Chen[SUP] 1 [/SUP], Chao Wan[SUP] 1 [/SUP], Yiwei Li[SUP] 1 [/SUP], Bi-Feng Liu[SUP] 1 [/SUP]
Affiliations
- PMID: 36373139
- PMCID: PMC9637550
- DOI: 10.1016/j.trac.2022.116814
Abstract
The Coronavirus disease 2019 (COVID-19) outbreak has urged the establishment of a global-wide rapid diagnostic system. Current widely-used tests for COVID-19 include nucleic acid assays, immunoassays, and radiological imaging. Immunoassays play an irreplaceable role in rapidly diagnosing COVID-19 and monitoring the patients for the assessment of their severity, risks of the immune storm, and prediction of treatment outcomes. Despite of the enormous needs for immunoassays, the widespread use of traditional immunoassay platforms is still limited by high cost and low automation, which are currently not suitable for point-of-care tests (POCTs). Microfluidic chips with the features of low consumption, high throughput, and integration, provide the potential to enable immunoassays for POCTs, especially in remote areas. Meanwhile, luminescence detection can be merged with immunoassays on microfluidic platforms for their good performance in quantification, sensitivity, and specificity. This review introduces both homogenous and heterogenous luminescence immunoassays with various microfluidic platforms. We also summarize the strengths and weaknesses of the categorized methods, highlighting their recent typical progress. Additionally, different microfluidic platforms are described for comparison. The latest advances in combining luminescence immunoassays with microfluidic platforms for POCTs of COVID-19 are further explained with antigens, antibodies, and related cytokines. Finally, challenges and future perspectives were discussed.
Keywords: COVID-19; Luminescence immunoassays; Microfluidic chips; POCTs.